Neogen Corporation Amortization of Debt Issuance Costs
Neogen Corporation (NEOG) reported Amortization of Debt Issuance Costs of $2.00 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-07-30
- Neogen Corporation amortization of debt issuance costs for the quarter ending 2026-05-31 was $500.00K, a 16.67% decline year-over-year.
- Neogen Corporation amortization of debt issuance costs for the quarter ending 2026-02-28 was $479.00K, a 45.57% decline year-over-year.
- Neogen Corporation amortization of debt issuance costs for the quarter ending 2025-11-30 was $482.00K, a 43.95% decline year-over-year.
- Neogen Corporation amortization of debt issuance costs for the quarter ending 2025-08-31 was $539.00K, a 37.33% decline year-over-year.
- Neogen Corporation amortization of debt issuance costs for fiscal 2026 was $2.00M, a 37.50% decline from fiscal 2025.
- Neogen Corporation amortization of debt issuance costs for fiscal 2025 was $3.20M, a 5.88% decline from fiscal 2024.
- Neogen Corporation amortization of debt issuance costs for fiscal 2024 was $3.40M, a 25.00% increase from fiscal 2023.
- Neogen Corporation amortization of debt issuance costs for fiscal 2023 was $2.72M.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 9 month as first filed | Amortization of Debt Issuance Costs 12 month | Amortization of Debt Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-05-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $979.00K derived: sum of 2 quarters · filed 2026-07-30 | $1.46M derived: sum of 3 quarters · filed 2026-07-30 | $2.00M 10-K · filed 2026-07-30 | ||
| 2026-02-28 | $479.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-04-09 | $961.00K derived: sum of 2 quarters · filed 2026-04-09 | $1.50M 10-Q · filed 2026-04-09 | $2.10M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-11-30 | $482.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-01-08 | $1.02M 10-Q · filed 2026-01-08 | $1.62M derived: sum of 3 quarters · filed 2026-07-30 | $2.50M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-08-31 | $539.00K 10-Q · filed 2025-10-09 | $1.14M derived: sum of 2 quarters · filed 2026-07-30 | $2.02M derived: sum of 3 quarters · filed 2026-07-30 | $2.88M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-05-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $1.48M derived: sum of 2 quarters · filed 2026-07-30 | $2.34M derived: sum of 3 quarters · filed 2026-07-30 | $3.20M 10-K · filed 2026-07-30 | $3.22M 10-K · filed 2025-07-30 | |
| 2025-02-28 | $880.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-04-09 | $1.74M derived: sum of 2 quarters · filed 2026-04-09 | $2.60M 10-Q · filed 2026-04-09 | $2.58M 10-Q · filed 2025-04-09 | $3.42M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2024-11-30 | $860.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-01-08 | $1.72M 10-Q · filed 2026-01-08 | $2.54M derived: sum of 3 quarters · filed 2026-07-30 | $3.40M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2024-08-31 | $860.00K 10-Q · filed 2025-10-09 | $1.68M derived: sum of 2 quarters · filed 2026-07-30 | $2.54M derived: sum of 3 quarters · filed 2026-07-30 | $3.40M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2024-05-31 | $819.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $1.68M derived: sum of 2 quarters · filed 2026-07-30 | $2.54M derived: sum of 3 quarters · filed 2026-07-30 | $3.40M 10-K · filed 2026-07-30 | $3.44M 10-K · filed 2024-07-30 | |
| 2024-02-29 | $861.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-04-09 | $1.72M derived: sum of 2 quarters · filed 2025-04-09 | $2.58M 10-Q · filed 2025-04-09 | $3.44M derived: sum of 4 quarters · filed 2025-07-30 | ||
| 2023-11-30 | $860.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-15 | $1.72M 10-Q · filed 2025-01-15 | $2.58M derived: sum of 3 quarters · filed 2025-07-30 | $3.44M derived: sum of 4 quarters · filed 2025-07-30 | ||
| 2023-08-31 | $860.00K 10-Q · filed 2024-10-10 | $1.72M derived: sum of 2 quarters · filed 2025-07-30 | $2.58M derived: sum of 3 quarters · filed 2025-07-30 | $3.58M derived: sum of 4 quarters · filed 2025-07-30 | ||
| 2023-05-31 | $860.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | $1.72M derived: sum of 2 quarters · filed 2025-07-30 | $2.72M derived: sum of 3 quarters · filed 2025-07-30 | $2.72M 10-K · filed 2025-07-30 | ||
| 2023-02-28 | $861.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-04-09 | $1.86M derived: sum of 2 quarters · filed 2024-04-09 | $1.86M 10-Q · filed 2024-04-09 | |||
| 2022-11-30 | $999.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-01-09 | $999.00K 10-Q · filed 2024-01-09 | ||||
| 2022-08-31 | $0.00 10-Q · filed 2023-10-10 | |||||
| 2022-05-31 | $0.00 10-K · filed 2024-07-30 | |||||
| 2021-05-31 | $0.00 10-K · filed 2023-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |